Evidence map›Paper›PMID 35011412›Full record

ReviewMolecules (Basel, Switzerland)2021

Nrf2 Regulation by Curcumin: Molecular Aspects for Therapeutic Prospects.

Seyed Hossein Shahcheraghi, Fateme Salemi, Niloufar Peirovi, Jamshid Ayatollahi, Waqas Alam, Haroon Khan, Luciano Saso

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Seyed Hossein ShahcheraghiInfectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd 8916978477, Iran.
Fateme SalemiSchool of Medicine, Islamic Azad University of Medical Sciences, Yazd 19395/1495, Iran.
Niloufar PeiroviSchool of Medicine, Tehran University of Medical Sciences, Tehran 1417614411, Iran.
Jamshid AyatollahiInfectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd 8916978477, Iran.
Waqas AlamDepartment of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.ORCID 0000-0001-8329-9180
Haroon KhanDepartment of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.
Luciano SasoDepartment of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University, 00185 Rome, Italy.ORCID 0000-0003-4530-8706
Abdul Wali Khan University Mardan · PKShahid Sadoughi University of Medical Sciences and Health Services · IRIslamic Azad University, Yazd · IRSapienza University of Rome · ITTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear factor erythroid 2 p45-related factor (2Nrf2) is an essential leucine zipper protein (bZIP) that is primarily located in the cytoplasm under physiological conditions. Nrf2 principally modulates endogenous defense in response to oxidative stress in the brain.In this regard, Nrf2 translocates into the nucleus and heterodimerizes with the tiny Maf or Jun proteins. It then attaches to certain DNA locations in the nucleus, such as electrophile response elements (EpRE) or antioxidant response elements (ARE), to start the transcription of cytoprotective genes. Many neoplasms have been shown to have over activated Nrf2, strongly suggesting that it is responsible for tumors with a poor prognosis. Exactly like curcumin, Zinc-curcumin Zn (II)-curc compound has been shown to induce Nrf2 activation. In the cancer cell lines analyzed, Zinc-curcumin Zn (II)-curc compound can also display anticancer effects via diverse molecular mechanisms, including markedly increasing heme oxygenase-1 (HO-1) p62/SQSTM1 and the Nrf2 protein levels along with its targets. It also strikingly decreases the levels of Nrf2 inhibitor, Kelch-like ECH-associated protein 1 (Keap1) protein.As a result, the crosstalk between p62/SQSTM1 and Nrf2 could be used to improve cancer patient response to treatments. The interconnected anti-inflammatory and antioxidative properties of curcumin resulted from its modulatory effects on Nrf2 signaling pathway have been shown to improve insulin resistance. Curcumin exerts its anti-inflammatory impact through suppressing metabolic reactions and proteins such as Keap1 that provoke inflammation and oxidation. A rational amount of curcumin-activated antioxidant Nrf2 HO-1 and Nrf2-Keap1 pathways and upregulated the modifier subunit of glutamate-cysteine ligase involved in the production of the intracellular antioxidant glutathione. Enhanced expression of glutamate-cysteine ligase, a modifier subunit (GLCM), inhibited transcription of glutamate-cysteine ligase, a catalytic subunit (GCLC). A variety of in vivo, in vitro and clinical studies has been done so far to confirm the protective role of curcumin via Nrf2 regulation. This manuscript is designed to provide a comprehensive review on the molecular aspects of curcumin and its derivatives/analogs via regulation of Nrf2 regulation.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicCarrier ProteinsCurcuminDrug Evaluation, PreclinicalGene Expression RegulationHumansNeoplasmsNeuroprotective AgentsNF-E2-Related Factor 2Oxidation-ReductionOxidative StressProtein BindingSignal TransductionTranscriptional ActivationAntineoplastic Agents, PhytogenicCarrier ProteinsCurcuminNeuroprotective AgentsNFE2L2 protein, humanNF-E2-Related Factor 2anticancer effectcurcuminfuture prospectmechanistic insightNrf2 regulation

Identifiers

PMID35011412
PMCPMC8746993
OpenAlexW4200285335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.